Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | SUITE 240 4960 PEACHTREE INDUSTRIAL BOULEVARD NORCROSS GA 30071 |
Tel: | N/A |
Website: | https://galectintherapeutics.com |
IR: | See website |
Key People | ||
Joel Lewis President, Chief Executive Officer, Director | Jack W. Callicutt Chief Financial Officer | Pol F. Boudes Chief Medical Officer |
Business Overview |
Galectin Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company's lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the United States Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. |
Financial Overview |
For the fiscal year ended 31 December 2023, Galectin Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 15% to $44.8M. Higher net loss reflects Interest expense increase from $1M to $2.8M (expense), Payroll and other increase of 49% to $4.3M (expense), Change in fair value of derivatives decrease from $557K (income) to $432K (expense). |
Employees: | 14 as of Feb 29, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $251.97M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$38.07M as of Dec 31, 2023 |
Net annual income (TTM): | -$44.81M as of Dec 31, 2023 |
Free cash flow (TTM): | -$32.97M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $46.08M as of Dec 31, 2023 |
Shares outstanding: | 61,903,672 as of Feb 29, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |